In advanced, metastatic stages of PDAC and colorectal cancer, regimens of ECM-degrading compounds such as LOX and HA inhibitors combined with conventional chemotherapeutics have so far failed to show additive or synergistic effects most likely due to the large, impenetrable ECM of late-stage cancers. The gene discussed is LOX; the disease is colorectal cancer.